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ABSTRACT 
 
Proliferation and migration of vascular endothelial cells (ECs) are critical steps in 
angiogenesis and are strictly controlled by a number extracellular stimula. Proangiogenic 
peptides binding to tyrosine kinase receptors (i.e. VEGFs and FGFs) are released by 
several cell types, including ECs and tumor cells. Proangiogenic intracellular signalling 
cascades involve many messengers working in a sort of network. In particular, in this 
review we describe the properties and functions of the intracellular calcium signals (Cai), a 
universal, evolutionary conserved and highly versatile pathway involved in the regulation of 
EC proliferation and migration. 
Angiogenic factors generate Cai rises via two mechanisms: entry from extracellular 
medium, through the opening of calcium-permeable channels in the plasmamembrane, or 
release from intracellular Ca2+ stores. Calcium entry, the main topic of this review, can be 
dependent on previously InsP3-activated emptying of calcium stores (store-operated Ca2+ 
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entry - SOCE), or independent on it (non store-operated Ca2+ entry - NSOCE). The 
intracellular pathways underlying endothelial Ca2+ entry involve, among the other 
pathways, arachidonic acid (AA) and nitric oxide (NO) metabolism. Even if some Ca2+ 
entry blockers are under clinical trial with encouraging results, a better knowledge about 
the molecular nature of proangiogenic Ca2+ channels and their intracellular regulation in 
healthy and pathological processes could lead to new and more powerful strategies in the 
therapeutical approaches aimed to interfere with altered tissue vascularization. Here, we 
discuss the state of the art in the field of calcium signaling and angiogenesis, the related 
recent literature and patents. 
 
INTRODUCTION 
Role of Ca2+ in the control of EC proliferation and migration 
Intracellular calcium (Cai) signals are a highly conserved and ubiquitous mode for 
the control of cell survival, proliferation, motility, migration, apoptosis, and differentiation [1-
4]. They are involved at different critical phases in the regulation of angiogenesis, both in 
healthy and in altered conditions [5-9]. 
Endothelial cells (EC) are the major actors of new blood vessels formation, and 
particular attention has been focused on them. During angiogenesis, ECs leave the 
preexisting vessel moving through the matrix, proliferate and finally stop their mitogenic 
activity and reorganize in a new tube [10-23]. Both migration and proliferation are strictly 
controlled by Cai dynamics, specifically modulated by extracellular proangiogenic agents 
such as vascular endothelial growth factors (VEGFs) and fibroblast growth factors (FGFs) 
[5-9, 24, 25].  
Calcium entry from external medium is usually mediated by Ca2+-permeable 
cationic channels in the plasmamembrane, which show varying degrees of selectivity and 
can support longer lasting signals (up to tens of minutes). While voltage-operated Ca2+ 
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channels open following a simple, direct stimulus such as a depolarization step, the 
activation of voltage-independent channels, largely prevalent in endothelium, needs the 
involvement of metabolic pathways stimulated by receptor tyrosine kinases (RTKs) or G-
protein-coupled receptors (GPCRs), leading to the production of second messengers that 
modulate channel activity [26, 27]. 
We usually distinguish between two major types of calcium entry: store-operated 
Ca2+ entry - SOCE, secondary to- and dependent on a previously activated depletion of 
intracellular stores, and non store-operated Ca2+ entry - NSOCE, carried by channels 
sensitive to intracellular messengers released upon receptor activation [28-30]. SOCE and 
NSOCE often coexist in the same cell, in some cases depending on agonist concentration 
or on the level of expression of the same channel. In some cell types, SOCE and NSOCE 
could cross-regulate [31-34].  
SOCE has been extensively associated with Ca2+ influx related to cell proliferation 
and involves the association of the endoplasmic Ca2+ sensor STIM-1 with channel-forming 
proteins including members of TRP and Orai1 [28, 35-41].  
Several other examples are related to proliferation dependent on NSOCE; for 
others, finally, the mechanism is not specified. Among the second messengers proposed 
to play a role in NSOCE activation, arachidonic acid (AA) and other lipidic molecules are 
the most relevant (see below). In particular, in bovine and human ECs from normal and 
tumoral tissues, AA opens calcium-permeable channels independently from store 
depletion and promotes Ca2+-entry-dependent cell proliferation and migration [42-52]. A 
store-independent Ca2+ channel, activated by low concentrations of AA, has been 
observed in HEK293 cells: this channel, responsible for IARC (arachidonate-regulated Ca2+ 
current), is not associated with cell migration and proliferation and its biophysical 
properties are significantly different from endothelial AA-activated calcium entry [31-34, 53, 
54]. 
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It is now well accepted that members of transient receptor potential (TRP) superfamily of 
channels contribute to agonist-activated Ca2+ entry in all tissues in a great number of 
physiological and pathological events [27, 55-63]. TRPs are cationic channels, some of 
which are directly activated by intracellular messengers, including diacylglicerol and AA 
[42, 50, 64].  
Endothelial TRP channels (19 different TRP members) regulate angiogenesis, 
vascular tone and permeability, EC proliferation, motility and differentiation. Moreover they 
are involved in the progression of a number of human cardiovascular diseases [24, 41, 56, 
58, 60, 61, 63, 65-82]. 
Beside TRPs, other channels play a role in proangiogenic signalling. Orai1 and 
Stim1, the components of the so-called calcium release activated currents (CRAC) 
channels, have been proposed to mediate VEGF-mediated SOCE in HUVECs and in vivo 
[39, 83]. In addition to their activity on mature ECs, Both TRPs and Orai1 are components 
of SOCE in endothelial progenitor cells (EPCs) that concur to neovascularization in tumors 
[83, 84].  
 
 
 
 
 
CALCIUM CHANNELS BLOCKERS 
 
Several Ca2+ channel blockers are available, with different chemical structure and 
variable selectivity and specificity [5, 6, 24, 25, 41, 72-82, 85-87]. Both voltage-dependent 
and independent Ca2+ channels are competitively blocked by inorganic ions, such as 
divalent transition ions (Ni2+, Cd2+, Co2+) and lanthanides (La3+, Gd3+). The use of this ions 
in clinical protocols is severely limited by their toxicity, and, at least in some cases, by their 
aspecificity.  
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A number of organic compounds are known to interfere with endothelial Ca2+ 
channels and angiogenic process [88] (figure 1). 
CAI. Carboxyamidotriazole (CAI, L651582, NSC 609974) is a synthetic Ca2+ influx blocker, 
extensively associated with inhibitory effects on cell proliferation [89-98]. The 
antiproliferative effects of CAI have been ascribed to its ability to inhibit intracellular 
pathways involving phospholipase-Cγ, InsP3 and arachidonic acid release, as well as to 
block Ca2+ channels. CAI inhibits proliferation and invasive properties of several tumor cell 
lines in vitro, including prostate, glioblastoma, hepatoma, small cell lung and breast-
derived cell lines. It also significantly reduces proliferation of several types of ECs 
(HUVECs, HAECs, BAECs) and affects angiogenesis induced in vitro by VEGF. The effect 
on angiogenesis is mediated by the block of calcium-mediated nitric oxide synthase-
vascular endothelial growth factor pathway. In HUVECs, a reduction of NO release was 
observed, while no significant effect on VEGFR, PLCγ, ERK1/2, NFAT activities was 
detected, supporting the high specificity of the drug. In BAECs, CAI partially inhibits 
calcium entry activated by AA, critically involved in the control of proliferation. Thus, the 
use of calcium channel inhibitors, at least in some cell types including endothelial and 
smooth muscle cells, suggests a role for NO and AA in the control of cell proliferation and 
secondarily of physiopathological processes (see below): however, the insurgence of 
complex feedbacks of AA and NO on calcium homeostasis renders the experimental data 
difficult to be clearly interpreted. 
On ECs, CAI-sensitive Ca2+ influx has been correlated to cell adhesion, spreading, 
proteolysis and migration, all processes involved in tumor invasion. Endothelial cell 
spreading on type IV collagen, but not on type I, is specifically regulated by CAI-sensitive 
Ca2+ influx, and the expression of metalloproteinase-2 is modulated by Ca2+ influx and 
down regulated by CAI. Inhibition of angiogenesis and metastasis has been detected in in 
vivo studies on several types of solid tumors. Administration of CAI, also in combination 
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with other drugs, in preclinical and clinical investigations stabilized solid tumors including 
carcinomas and melanomas. 
Imidazole derivatives. Imidazole derivatives, such as clotrimazole, econazole, 
miconazole, ketoconazole, are antimycotic drugs widely used for the treatment of yeast 
infections [5, 99]. Imidazole antimycotics are potent inhibitors of many mammalian 
cytochrome P450-dependent reactions. Secondary to their effects on cytochrome P450 
activity, they have also been extensively used as non-specific blockers of Ca2+ influx. 
Moreover, other effects on Ca2+ homeostasis have been described: miconazole, 
clotrimazole and econazole, in the µM range, promote Ca2+ entry in canine kidney cells; 
clotrimazole inhibits the activity of the sarcoplasmic reticulum Ca2+ pump in rabbit 
cardiomyocytes. Notably, some imidazole derivatives have been shown to affect the 
activity of kinases strongly involved in mitogen-induced intracellular signalling. The 
compound SK&F 96365 is widely used, and it is commonly suggested to act on TRPC 
channels [100]. However, it has been in turn classified as a specific blocker of SOCs, 
NSOCs, or as a non-specific blocker, acting also on VOCs. Moreover, other aspecific 
effects have been reported, both of activation and block of other types of channels. The 
isoquinoline derivative LOE-908 is an inhibitor of SOCE and NSOCE that interferes with 
endothelial permeability. It has been used as TRPC inhibitor [88, 100]. 
Calcium Trifluoroacetate. A recent report described the effects of Calcium 
Trifluoroacetate, Ca(TFA)2, a complex, poorly dissociated salt with low toxicity [101]. 
Ca(TFA)2 inhibits VEGF-induced ECs proliferation in vitro and angiogenesis in vivo. 
Interestingly, it triggers [Ca]i signals in HMECs preventing [Ca]i signaling induced by 
VEGF [102]. The detailed mechanism of through which Ca(TFA)2 reduces the efficiency of 
signal transduction triggered by the growth factor has not been investigated. It could be 
able to activate calcium-permeable channels, as well as to regulate calcium extrusion 
systems and potassium channels.  
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CALCIUM SIGNALS RELATED TO ANGIOGENESIS 
 
Proangiogenic factors. Most angiogenic factors (FGFs, EGF, PDGF, VEGFs, IGF-I), 
exert their effect by the interaction with intrinsic tyrosine kinase receptors (RTKs); 
cytokines (such as interleukins, ILs) bind to receptors associated with cytosolic TKs, while 
other growth factors (such as bradikinin, ATP, oxytocin, colecystokinin, many 
neuropeptides) act via G-protein-coupled receptors (GPCRs) [6, 10, 103-111]. While each 
of these classes has its peculiarities, and involves specific cascades of intracellular events, 
the distinction is actually not so sharp, since in many instances crosstalks between 
different pathways have been described and may represent a general and physiological 
process. Moreover, a high degree of  convergence on the same effector (a channel or an 
enzyme) is quite usual, suggesting that some signalling modules (among them calcium 
signals) are well conserved and are employed by different agonists in different contexts; 
this finding prompts another question, i.e. how such an interwoven web of signals can be 
reconciled with the evidence that different factors can exert specific and unique effects on 
the same cells (figure 2).  
 Calcium rises activated upon membrane receptor recruitment have been 
detected in virtually every type of normal and tumor-derived cell lines. Cai signals are very 
early events, starting typically after a delay of seconds from the agonist exposure. On the 
basis of the time course, we can distinguish four types of Cai increases: a single spike 
usually due to release from intracellular stores; a slower and more persistent Ca2+  signal 
dependent on Ca2+  entry from the extracellular medium; a biphasic Cai elevation resulting 
from the combination of the two mechanisms; finally, Cai oscillations. 
In particular, a striking feature of proangiogenic Cai signalling is its heterogeneity. Both 
amplitude and time course of the response is highly variable from cell to cell. This 
observation can be ascribed to the differential expression of the receptors, the Ca2+ 
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channels, or the intracellular machinery leading to the response. Vascular endothelium is a 
heterogeneous tissue: macro- and microvascular EC lines, as well as ECs obtained from 
different tissues, display biochemical and functional differences (see also concluding 
remarks). 
Angiogenic inhibitors: Angiostatin and Endostatin. A number of endogenous 
inhibitors of angiogenesis are associated with tumors: the best known are angiostatin and 
endostatin [112-114]. Angiostatins are constituted by the first three, four, or five kringle 
domains of the plasminogen molecule: they are released by matrix metalloproteases 
secreted by tumor-infiltrating macrophages . Endostatin is a 20 kDa C-terminal fragment of 
collagen XVIII, probably generated by proteases and elastates activity [113, 115-117]. 
Endostatin and angiostatin inhibit EC migration and proliferation, and both induce EC 
apoptosis. Interestingly the antiproliferative effects of angiostatin seem specific for ECs 
while other cell types are not affected. Even if some studies have been performed by the 
analysis of acute intracellular effects of these peptides, several aspects of their 
mechanisms of action (including the putative membrane receptors) are unknown [112, 
114, 115]. Cai signalling related to angiostatin and endostatin stimulation has been 
described in BAECs, HMECs, and CPAECs [117]. The response is dependent on INSP3 
release following PLC activation and is composed by an initial release from intracellular 
stores followed by a prolonged Ca2+ entry. Another interesting observation is that 
prolonged exposure to endostatin attenuates acute calcium signalling in response to 
subsequent treatment with VEGF and FGF. Kringle domains of urokinase, another 
antiangiogenic endogenous factor, are also able to promote calcium increases in HUVECs 
but not in other cell types. 
 
ARACHIDONIC ACID, NITRIC OXIDE AND Ca2+  
 
 9 
Arachidonic acid metabolism and Ca2+ 
In resting cells, AA is stored within the cell membrane, esterified to glycerol in 
phospholipids. Three enzymes (the phospholipases A2, C and D), with different sites of 
attack on the phospholipid backbone, mediate the deacylation reaction that releases the 
fatty acid  [5, 51, 99]. While PLA2 releases arachidonate in a single-step reaction, PLC 
and phospholipase D (PLD) do not produce AA directly; rather, they generate lipid 
products containing arachidonate, respectively DAG and phosphatidic acid; the latter can 
be metabolized to DAG by phosphatidic acid phosphatase (PA-PH). From DAG, AA can 
be subsequently released by diacylglycerol lipase (DAG lipase) .  
In mammalian cells, PLA2 is present in several isoforms, classified in 11 groups differing in 
structure, intracellular localization, regulation, calcium dependence and pharmacological 
inhibition [118-124]. One of them is the secretory PLA2 (sPLA2), a low molecular weight 
enzyme (14 kDa), whose activity is dependent on high calcium concentration (in the 
millimolar range); the cytosolic PLA2 (cPLA2, 85 kDa) is the form that has been 
investigated more extensively and is the enzyme stimulated mainly by growth factors 
through a MAPK-dependent phosphorylation on Ser-505. Its activation requires also a 
translocation to the membrane, in order to interact with its substrate, in a calcium-
dependent fashion, at the physiological Ca2+ levels reached after agonist stimulation. 
Another form of PLA2 (iPLA2) is Ca2+-independent and its functional roles are not well 
characterized; recently, in a colon carcinoma cell line (Caco-2 cells), evidence has been 
provided for its involvement in serum-induced AA release and cell proliferation. 
In vascular ECs, bFGF receptor activation leads to the recruitment of several 
adapter proteins (FRS2, Grb2) followed by the indirect activation of ras and the mitogen 
activated protein kinase (MAPK) cascade. MAPK triggers a series of downstream events, 
including the activation of phospholipase A2 (PLA2): this enzyme in turn catalyzes the 
hydrolysis of phospholipids at the sn-2 position, where arachidonic acid (AA) is acetylated.  
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AA metabolites and angiogenesis 
Once released, free AA has different potential fates: direct regulation of several 
target proteins (ion channels, enzymes), diffusion outside the cell, reincorporation into 
phospholipids and metabolism [122, 125]. Metabolism of AA is carried out by three 
enzyme families: cyclooxygenases (COX), which generate prostaglandins, prostacyclins 
and thromboxanes, lipoxygenases (LOX), that produce leukotrienes, and cytocrome P450 
monooxygenases, yielding a variety of epoxyeicosatrienoic and 
hydroperoxyeicosatetraenoic acids.  All these compounds are collectively called 
eicosanoids, and act as autocrine or paracrine regulators of a variety of functions, 
particularly in inflammatory processes. Notably, several lines of evidence suggest their 
involvement in the control of EC proliferation and angiogenesis progression. In ECs from 
bovine adrenal cortex capillaries, AA release and the LOX pathway play a critical role in 
vascular cell proliferation induced by bFGF, PDGF and serum. In ECs isolated from bovine 
aorta, cPLA2 is activated by bFGF through p42 MAPK-dependent phosphorylation, 
triggering the release of AA. Moreover, in the same cell type, bFGF is a potent stimulator 
of proliferation through the LOX pathway of AA metabolism. Therefore, in general, LOX 
metabolites display mitogenic activity on ECs, while eicosanoids produced by the 
cyclooxygenase pathway are considered to be predominantly involved in the stimulation of 
migration. Some of the pathways cited above lead to other well known regulators of 
calcium-permeable channels, such as diacylglicerol (DAG) and InsP3. 
AA and Ca2+ 
AA itself and some of its metabolites are able to induce Cai increases in ECs. The 
direct effect of AA, independent on its metabolites, has been revealed via two major 
strategies: the pharmacological inhibition of COX, LOX and P450 MO (using indomethacin, 
NDGA, econazole derivatives and other compounds, some of which highly aspecific) or 
the use of ETYA, an AA analogue not metabolized by the enzymes cited above, able to 
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mimic at least partially AA-dependent Ca2+ entry. In bovine aortic ECs (BAECs), human 
microvascular ECs, and tumor-derived human ECs (TECs, see below), AA induces a 
sustained NSOCE. Calcium entry is due to different Ca2+ channels, including TRPs, and 
regulates EC proliferation and migration. In the same cells, NSOCE is also activated by 
angiogenic factors (bFGF and VEGF) [42, 44, 45, 47-49, 51, 52, 126-128].  
 
Nitric oxide metabolism and calcium 
NO and angiogenesis 
Several lines of evidence point to a relationship between NO release and 
angiogenesis progression [129, 130]. However, the selective role of NO in the different 
steps of endothelial biochemical modifications during angiogenesis is debated. Many 
angiogenic factors increase the expression of endothelial NO synthase (eNOS) and 
stimulate the release of endothelium-derived NO. VEGF augments the endothelial 
expression of NOS, and stimulates the biosynthesis of NO from cultured human umbilical 
venous ECs and vascular segments of rabbit thoracic aorta. Similarly, transforming growth 
factor beta (TGFß) or bFGF trigger NO release in ECs. 
A number of different approaches show the global involvement of NO on angiogenesis 
[129-136]. Stimulation of human umbilical venous ECs in a three-dimensional gel with 
bFGF or VEGF triggers NO production and let them to form capillary-like structures. This 
process is abolished by the NOS antagonist Nw-nitro-l-arginine methylester (l-NAME). The 
same effect of L-NAME is observed in the rabbit cornea, another model of angiogenesis. 
NO appears to affect more than one step of angiogenesis process, acting as a freely 
diffusible pleiotropic factor on different cell types: in particular, this ability is clearly exerted 
on endothelial and smooth muscle cells. NO is an endothelial survival factor, inhibiting 
apoptosis. It increases proliferation on some EC types and reduces it in others. NO also 
promotes endothelial migration, possibly via the activation of podokinesis. In addition, NO 
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enhances matrix–endothelial cell interaction by inducing the expression of αvβ3 and by 
increasing disruption of the extracellular matrix via the bFGF-induced up regulation of 
urokinase-type plasminogen activator. Intriguing evidences point to the well known ability 
of NO to act as vasodilator: increased flow in the skeletal microcirculation has been 
observed to trigger endothelial cell proliferation and it is therefore possible that in addition 
to its direct effects on endothelial cell proliferation, NO may influence endothelial growth 
indirectly by increasing blood flow locally. Detailed mechanisms underlying this process 
are not known, but the effect of NO on endothelial mechanically gated calcium-permeable 
channels activated by shear stress could be a critical route. Finally, it should be noted that 
NO can induce the synthesis and release of VEGF from vascular cells, giving rise to a 
positive feedback mechanism. 
NO and Ca2+ 
NO release is controlled by calcium elevation, due to eNOS calcium-sensitivity 
Accordingly to its plasmamembrane association, eNOS has been proposed to be 
preferentially recruited by calcium entry more than by calcium release from intracellular 
stores in bovine aortic ECs. Moreover, prolonged capacitative calcium entry strongly 
activates eNOS. On the other hand, eNOS can be activated by calcium-independent 
additional mechanisms, such as PI3K-Akt signalling. 
Nitric oxide affects endothelial calcium homeostasis in different ways [48, 49, 132]. 
Flow induced calcium entry, mediated by mechanically-gated calcium-permeable 
channels, is sensitive to a protein kinase G-activated conductance in rat aortic ECs. In 
porcine pulmonary artery ECs (PAECs) NO upregulates the expression of cyclic nucleotide 
gated channels and activate a cGMP-independent calcium entry. Moreover, in calf 
pulmonary artery ECs (CPAECs), NO inhibits CCE and enhances endoplasmic reticulum 
uptake of calcium. In these reports, NO is not explicitly associated with cell proliferation: 
nevertheless, due to the ability of several mitogens to release this messenger, it could play 
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a critical role in the control of calcium signals related to proliferative processes. 
Interestingly, NO has been recently suggested as a mediator of AA-induced calcium entry 
in smooth muscle cells and isolated mouse parotid cells. 
Notably the pathways leading to proangiogenic Cai increase are Ca2+-dependent: some 
members of the phospholipase A2 (PLA2) (that release AA), PLC (releasing DAG and 
InsP3), NOS and TK families are calcium-regulated. This may establish a non-linear 
positive loop contributing to the complexity of the signal. 
 
SPECIFICITY OF CALCIUM SIGNALLING 
 
Spatial dynamics of calcium signals: from elementary to global events 
Technical improvements during the last decades revealed the existence of localized 
Cai signals (microdomains called blips, puffs, quarks) in different cell types, including ECs 
[48, 137-146]. When diffusional and regenerative mechanisms are triggered, these 
elementary events evolve to global Cai waves involving all the cell volume, including the 
nucleus. Calcium microdomains have been detected in several regions: near the 
plasmamembrane Ca2+ channels and close to ER releasing sites. Such signals can remain 
localized and activate and/or recruit effectors in the vicinity. In bovine vascular ECs, focal 
ATP stimulation results in spatially restricted Ca2+ release and SOCE. Mitochondria have 
been shown to play a critical role in the local regulation of capacitative Ca2+ entry and 
store refilling in HUVECs. Caveolae, special membrane microdomains, may play a 
relevant role in controlling the spatial and temporal pattern of Cai signalling. Endothelial 
caveolae include several components of intracellular signalling such as Ca2+ pumps, InsP3 
receptor-like proteins, eNOS, PLC, PKC, and both GPCR and RTKs. 
Temporal dynamics of calcium signals and gene expression   
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Intracellular calcium signals trigger arrays of both rapid and sustained events, 
respectively ranging in seconds/minutes and hours/days. These responses are highly 
variable from a cell type to another. Moreover, single cell analysis points to the existence 
of a variability also in the same cell population, depending on quali-quantitative differential 
expression of receptors, signalling molecules, Ca2+ channels and other elements of 
intracellular signalling. 
The detailed mechanisms underlying the complex relationship between Ca2+ signals 
with different time courses and gene activation are only partially known [147]. In T and B 
lymphocytes maturation and activation, the induction of a small transient spike due to Ca2+ 
release from internal stores is sufficient to activate a specific pattern of signalling 
molecules and transcription factors such as NF-kB and JNK [148-153]. However this brief 
calcium event fails to activate other transcription factors, notably NFAT. In resting cells the 
phosphorylated form of this protein is located in the cytosol: after stimulation, it is 
dephosphorylated by the Ca2+-dependent phosphatase calcineurin and translocates in the 
nucleus. As a result, only a long lasting Cai increase, mediated by Ca2+ entry, is able to 
sustain NFAT activation. DNA microarray analysis on T lymphocytes confirms these 
evidence providing further informations: Ca2+-dependent signalling mediates both gene 
induction and gene repression by integration of inputs from calcium store depletion, Ca2+ 
entry, calcineurin activation and other downstream pathways. Some authors suggest an 
opposite role of CREB and NFAT transcription factors in the control of cell growth and 
proliferation. Even if these observations have been provided on a particular and highly 
specialized cell type, they may be useful as a working hypothesis on ECs. A relevant goal 
could be to identify the role of Cai signals in the switch between the different events 
involving ECs during angiogenesis: proliferation, migration and reorganization in a new 
vessel.
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CURRENT AND FUTURE DEVELOPMENTS 
 
Several independent lines of evidences suggest that endothelial calcium signals 
play a role in physiological and pathological vascularization. In particular, Ca2+ entry 
mediated by proangiogenic Ca2+-permeable channels regulates endothelial migration and 
proliferation. For these reasons, this event could be a target for the development of anti-
cancer approaches aimed to inhibit tumor vascularization. However, despite the discovery 
of several natural or synthetic Ca2+  channels blockers, some relevant concerns limit their 
therapeutical applications. Firstly, a great amount of Ca2+ channel types are involved, 
activated or modulated by proangiogenic factors. In addition, while the same intracellular 
messenger can modulate different Ca2+ channels, some proangiogenic Ca2+ channels (i.e. 
TRPs) are co-regulated by a variety of intracellular pathways. Finally, the pattern of 
endothelial Ca2+ channels and their functional roles are strictly dependent on the tissue-
specific microenvironment. This great variability has been well established for normal 
tissues, and particularly evident between macro- and microvasculature. More recently, this 
observation was extended to ECs obtained from human tumoral tissues. 
 Tumor neovascularization can be achieved by the recruitment of cell types other than 
ECs, including tumor cells, inflammatory cells and endothelial precursors, giving rise to 
very peculiar blood vessels [11, 104]. Tumor-derived human ECs (TECs) differ from 
normal ones for their functional behaviour and intracellular signalling [154, 155]. In 
particular, breast carcinoma- derived human ECs are more responsive to proangiogenic 
stimula in terms of calcium signals. The expression and functional role of some TRPs is 
altered [6, 42, 44, 45, 47, 128, 156-162].  
A broad proteomic approach, combined to high-throughput functional screening 
assays, would be required to provide a more detailed information on the expression and 
regulation of Ca2+ channels involved in vascularization in health and disease. 
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Figure Legends 
 
Figure 1 
Structure of some widely used blockers of proangiogenic Ca2+ entry. 
Carboxyamidotriazole (CAI), Calciumtrifluoroacetate (Ca(TFA)2), SKF (SK&F 96365). 
 
Figure 2 
Interplay among AA, NO and Ca2+ in endothelial cells. 
Tyrosine kinase receptors (RTKs), phospholipase D (PLD), phospholipase C (PLC), 
phospholipase A2 (PLA2), phosphatidic acid phosphatase (PA-PH), diacylglycerol lipase 
(DAG lipase), mitogen activated protein kinase (MAPK), cyclooxygenases (COX), 
lipoxygenases (LOX), cytocrome P450 monooxygenases (P450-MO), Guanylyl Cyclase 
(GC), endothelial Nitric Oxide Synthase (eNOS), proteine kinase A (PKA), cytosolic free 
calcium concentration ((Ca)i). 
Dashed lines show the feedback effects of Ca2+ on intracellular signalling. 
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